Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
about
Pharmacogenetic studies update in type 2 diabetes mellitusPharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agentsPharmacogenomics in type 2 diabetes: oral antidiabetic drugs.Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.Prediction of hepatic clearance in human from in vitro data for successful drug development.Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective.Impact of OATP transporters on pharmacokinetics.Association of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C polymorphisms and overall survival of breast cancer patients after tamoxifen therapyPersonalized medicine in diabetes mellitus: current opportunities and future prospectsPharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine.Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteersGenome-wide study of methotrexate clearance replicates SLCO1B1.Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions.The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.Pharmacogenetics of oral antidiabetic drugs.A variation in KCNQ1 gene is associated with repaglinide efficacy on insulin resistance in Chinese Type 2 Diabetes Mellitus Patients.Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.Pharmacogenetics and personalized treatment of type 2 diabetesHepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects.Genetic polymorphisms in placental transporters: implications for fetal drug exposure to oral antidiabetic agents.Current understanding of hepatic and intestinal OATP-mediated drug-drug interactions.Towards safer and more predictable drug treatment--reflections from studies of the First BCPT Prize awardee.The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs.Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.Stratified medicine for the use of antidiabetic medication in treatment of type II diabetes and cancer: where do we go from here?Pharmacogenomics of glinides.The role of organic anion transporting polypeptides in drug absorption, distribution, excretion and drug-drug interactions.Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro.Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics.Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanismPharmGKB very important pharmacogene: SLCO1B1.Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast.Symptomatic hypoglycemia associated with trimethoprim/sulfamethoxazole and repaglinide in a diabetic patient.Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential.Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method.Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism.Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite.The pregnane X receptor agonist St John's Wort has no effects on the pharmacokinetics and pharmacodynamics of repaglinide.Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers.Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers.
P2860
Q26739350-2B11D39B-EA3E-4611-9289-592EC5178C99Q26751138-44A65B58-BF2D-4E2F-98DD-BE70DD9C0AAFQ30248914-975D1A90-FF57-4817-B5F1-88016B135E2BQ30571118-631FD9ED-5E21-4D72-8ABF-6FBA2455086CQ33437736-7651BFB9-2052-48F5-A135-B7EBC830A951Q33993320-AC0B0C77-5989-4D1A-B7F3-7B1E83B32B0AQ34612244-0382E5AF-4F78-4E29-8E52-66D36E072FD4Q35135638-56F3545A-0AE5-48AD-9A88-AE99AC26789EQ35779453-DBB77FFE-D620-4CB1-8D34-8F498FF78419Q36441465-0637B350-3AAB-424F-A9B4-2F7E68E32E22Q36475040-EBE8E0B9-A21C-4E07-8968-EF0712F98D03Q36595293-BD58B181-3322-42CA-B6CE-C96822F15B5AQ37120923-F900E271-64D8-4B60-951D-EE7EBC4AFA84Q37175829-F59CFD9D-5827-49C1-8BAC-232A92798DB4Q37353476-57A17F53-2A6E-4A1D-BC89-3627C9A100E5Q37421626-1DB4A46F-C4D0-47FF-A2E7-BF8C147DC8F2Q37481450-F8866C54-B5C0-4A2E-825A-3368B3AAE791Q37508445-4CEED5FE-E710-4D96-9C23-5060916617D9Q37680968-5C49F187-FAF8-4A17-BDD0-C146E746A265Q37830057-21722E6D-8808-4444-A3BA-2D8F1AC63617Q37960129-4AD4C670-8C25-41B3-8AA8-81ED2E344D7EQ37986145-EB839651-83A4-4495-9C25-9A5118C3C33CQ38110432-FB78985D-42F5-48F7-8C46-C83422796C5CQ38199526-F538D2C2-197D-443E-8068-6FC230E1DFA0Q38270699-5B989323-F726-4B3B-BAF4-BF54412420B4Q38307994-883D484F-9FEE-4CA4-A4A7-D6FFE2AF43AAQ38991373-99B30E90-A58C-4EF0-B1D7-CE63299B2C4CQ39444051-7E77C0CA-EF17-49A1-BF00-5770C990AB1AQ40180361-8FAD1C5D-2880-4EC9-8775-EDCA0870F8CCQ41589503-79C5244F-50AE-40A8-90E4-DBD20FAC8D65Q42726145-C9FD8F0C-80CA-410C-8A0F-3DD550F0E10EQ42997336-F354FAAE-7E72-48C3-9B54-A19929985DBBQ43144700-509F2A75-8225-428E-A028-9453DF2F6A21Q43767845-408E777B-90EB-44F8-A0D1-C20D18B04879Q43940364-24AD22DE-6348-4A8F-816C-7382FF560FBCQ46111551-E335E800-7224-4042-A3A1-1B33B6001C18Q46431899-211098D9-7EDC-4EBA-BB90-CDE286901697Q48809049-BEFC5170-AE53-4370-8EC6-DB36E8DCEBD5Q54048653-72118A29-158F-4639-B492-40CDBD2EA5B5Q54387375-BACA1596-5F85-47DB-86FD-B9F10A47128D
P2860
Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Different effects of SLCO1B1 p ...... f repaglinide and nateglinide.
@en
Different effects of SLCO1B1 p ...... f repaglinide and nateglinide.
@nl
type
label
Different effects of SLCO1B1 p ...... f repaglinide and nateglinide.
@en
Different effects of SLCO1B1 p ...... f repaglinide and nateglinide.
@nl
prefLabel
Different effects of SLCO1B1 p ...... f repaglinide and nateglinide.
@en
Different effects of SLCO1B1 p ...... f repaglinide and nateglinide.
@nl
P2860
P50
P356
P1476
Different effects of SLCO1B1 p ...... f repaglinide and nateglinide.
@en
P2093
Annikka Kalliokoski
P2860
P304
P356
10.1177/0091270007311569
P577
2008-01-10T00:00:00Z